Parameter | mean | SE | Parametersa | Distribution | Source | |||
---|---|---|---|---|---|---|---|---|
Clinical data | ||||||||
 Monitoring performanceb (proportions) | ||||||||
  True favourable | 0,53 | 0,04 | 0,53/0,04 | Dirichlet | [10] | |||
  True unfavourable | 0,24 | 0,05 | 0,24/0,05 | Dirichlet | [10] | |||
  False favourable | 0,17 | 0,07 | 0,17/0,07 | Dirichlet | [10] | |||
  False unfavourable | 0,07 | 0,09 | 0,07/0,09 | Dirichlet | [10] | |||
 Chemotherapy related toxicities | ||||||||
  Vomiting | 3×AC | 0,05 | 0,02 | 5/98 | beta | [24] | ||
3×DC | 0,24 | 0,04 | 24/77 | beta | [24] | |||
  HFS | 3×DC | 0,22 | 0,04 | 23/80 | beta | [24] | ||
  Neutropenia | 3×AC | 0,85 | 0,04 | 86/15 | beta | [24] | ||
3×DC | 0,72 | 0,04 | 74/29 | beta | [24] | |||
  Desquamation | 3×DC | 0,05 | 0,02 | 5/98 | beta | [24] | ||
  CHF | 3×AC | 0,002 | 0,20 | 1/359 | beta | [23] | ||
6×AC | 0,02 | 0,60 | 11/349 | beta | [23] | |||
  AML/MDS | 3×AC | 0,003 | 0,001 | 12/4471 | beta | [25] | ||
6×AC | 0,005 | 0,001 | 12/2372 | beta | [25] | |||
Transition probabilities | ||||||||
 Relapse | ||||||||
  RG-NACT; False favourable/unfavourable | Tp1 | 0,14 | 0,06 | 4/24 | beta | [10] | ||
Tp2 | 0,29 | 0,08 | 8/20 | beta | [10] | |||
Tp3 | 0,47 | 0,09 | 13/15 | beta | [10] | |||
Tp4 | 0,44 | 0,09 | 12/16 | beta | [10] | |||
Tp5 | 0,40 | 0,09 | 11/17 | beta | [10] | |||
  RG-NACT; True favourable/unfavourable | Tp12-5 | 0,00 | NA | - | fixed | assumption | ||
  HR RFS (RG-NACT vs. conventional-NACT) | 0,50 | 0,20 | 0,50/0,20 | Normal truncated | assumption | |||
  Conventional-NACT | Tp1 | 0,03 | - | - | - | [10] | ||
Tp2 | 0,06 | - | - | - | [10] | |||
Tp3 | 0,08 | - | - | - | [10] | |||
Tp4 | 0,05 | - | - | - | [10] | |||
Tp5 | 0,04 | - | - | - | [10] | |||
Breast cancer specific death | ||||||||
  False favourable/unfavourable | Tp1 | 0,00 | NA | - | fixed | assumption | ||
Tp2 | 0,04 | 0,02 | 5/109 | beta | [27] | |||
Tp3 | 0,12 | 0,03 | 14/100 | beta | [27] | |||
Tp4 | 0,06 | 0,02 | 7/107 | beta | [27] | |||
Tp5 | 0,19 | 0,04 | 22/92 | beta | [27] | |||
  HR BCSS (RG-NACT vs. conventional-NACT) | 0,64 | 0,13 | 0,64/0,13 | normal | [11] | |||
  Conventional-NACT | Tp1 | 0,00 | NA | - | fixed | assumption | ||
Tp2 | 0,06 | - | - | - | [27] | |||
Tp3 | 0,19 | - | - | - | [27] | |||
Tp4 | 0,09 | - | - | - | [27] | |||
Tp5 | 0,28 | - | - | - | [27] | |||
Utilities | ||||||||
 Chemotherapy | 0,62 | 0,04 | 94/58 | beta | [39] | |||
 Neutropenia | 0,53 | 0,01 | 557/488 | beta | [40] | |||
 Anxiety | 0,68 | 0,06 | 40/19 | beta | [43] | |||
 Vomiting | 0,52 | 0,08 | 17/16 | beta | [41] | |||
 HFS | 0,50 | 0,10 | 12/12 | beta | [41] | |||
 Desquamation | 0,59 | 0,01 | 1041/721 | beta | [40] | |||
 CHF (average grade III/IV) | 0,55 | - | - | beta | [42] | |||
  CHF grade III | 0,59 | 0,02 | 360/250 | beta | [42] | |||
  CHF grade IV | 0,51 | 0,05 | 52/50 | beta | [42] | |||
 MDS/MLA | 0,26 | 0,01 | 500/1423 | beta | [55] | |||
 DFS | 0,80 | 0,03 | 196/49 | beta | [39] | |||
 R (average loco-regional and metastatic) | 0,73 | - | - | beta | [39] | |||
  Loco-regional relapse | 0,68 | 0,03 | 226/104 | beta | [39] | |||
  Metastatic relapse | 0,78 | 0,04 | 104/30 | beta | [39] | |||
Scenarios and resource modelling | ||||||||
 Incidental findings |  |  |  |  |  | |||
  All | 0,18 | 0,01 | 270/1265 | beta | [29] | |||
  Malign | 0,20 | 0,02 | 55/270 | beta | [29] | |||
 MRI contraindications |  |  |  |  |  | |||
  Impaired renal function | 0.07 | 0.1c | 0.45/5.54 | beta | [49] | |||
  Gadolinium allergy | 0.0003 | 0.01d | 0.08/29 | - | [44] | |||
  Body ferrous parts | 0.58 | 0.1 | 0.26/4.21 | beta | [45] | |||
  Claustrophobia | 0.02 | 0.1 | 0.02/0.94 | beta | [48] | |||
  Uptake | 0.04 |  | 20-100 % | fixed | assumption | |||
  MRI technologists with ATS | 0.26 |  | - | fixed | [50] | |||
Costs | ||||||||
 Parameter | Unit costs | Unit measure | Mean resource use | Mean cost | SEe | Distribution | Source | |
Chemotherapy | Â | |||||||
 6×AC | Doxorubicin | €204 | 90 mg | 5,3 | €1306 | €326 | Gamma | [31] |
Cyclophosphamide | €45 | 1080 mg | 6,4 | €239 | €60 | Gamma | [31] | |
Peg-filgrastim | €849 | 1 mg | 6 | €5096 | €1274 | Gamma | [56] | |
Pharmacy preparation | €45 | Per course | 6 | €267 | 67 | Gamma | NKI | |
Day care | €286 | Day | 6 | €1718 | €430 | Gamma | [30] | |
Oncologist’s visit | €109 | Visit | 6 | €653 | €163 | Gamma | [31] | |
Total |  |  |  | €9279 |  |  |  | |
 3×AC/3×DC | Doxorubicin | €204 | 90 mg | 3,2 | €653 | €163 | Gamma | [31] |
Cyclophosphamide | €45 | 1080 mg | 2,7 | €120 | €30 | Gamma | [31] | |
Peg-filgrastim | €849 | 1 mg | 3 | €2548 | €637 | Gamma | [56] | |
Docetaxel | €959 | 108 mg | 3,3 | €3195 | €799 | Gamma | [31] | |
Capecitabine | €27 | 4500 mg | 29,9 | €821 | €205 | Gamma | [31] | |
Pharmacy preparation | €45 | Per course |  | €267 | €67 | Gamma | NKI | |
Day care | €286 | Day | 6 | €1718 | €430 | Gamma | [30] | |
Oncologist’s visit | €109 | Visit | 6 | €653 | €163 | Gamma | [31] | |
Total |  |  |  | €9974 |  |  |  | |
Monitoring | ||||||||
 MRI scan | ||||||||
 Hospital costs | €163 | Scan | 1 | €163 | €41 | Gamma |  | |
 Specialists fees | €52 | Scan | 1 | €52 | €13 | Gamma |  | |
  Total |  |  |  | €215 |  |  |  | |
 Confirm incidental findings | €149 | Episode | 1 | €149 | €37 | Gamma |  | |
Chemotherapy related toxicities | ||||||||
 Neutropenia | €14397 | Episode | 1 | €14397 | €425 | Gamma | [35] | |
 Vomiting | €92 | Episode | 1 | €92 | €23 | Gamma | [57] | |
 CHF | €18225 | Episode | 1 | €18225 | €4556 | Gamma | [33] | |
 MDS/MLA | €112946 | Episode | 1 | €112946 | €28236 | Gamma | ||
Health states | ||||||||
 DFS | In & out –patient | €2793 | Episode | 1 | €2793 | €563 | Gamma | [36] |
Drugs | €79 | Episode | 1 | €79 | €20 | Gamma | [36] | |
Total |  |  |  | €2872 |  |  |  | |
 R | Local relapse | |||||||
 In & out -patient | €12497 | Episode | 1 | €12497 | €1692 | Gamma | [36] | |
 Drugs | €2336 | Episode | 1 | €2336 | €584 | Gamma | [36] | |
Distant metastasis | Â | Â | Â | Â | Â | Â | Â | |
 In & out -patient | €11645 | Episode | 1 | €11645 | €1346 | Gamma | [36] | |
 Drugs | €5772 | Episode | 1 | €5772 | €1443 | Gamma | [36] | |
Total |  |  |  | €16125 |  |  |  | |
 BC death | €8296 | Episode | 1 | €8296 | €2074 | Gamma | [36] |